CURE241220C94000
- 0.00
- 0.000.00%
Direxion Daily Healthcare Bull 3X Shares Newsroom
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Musk causes a commotion at Capitol Hill, is a "Trump 2.0" prototype emerging?
Analysis suggests that Musk's recent act of detonating a political nuclear bomb may be a rehearsal for the Trump 2.0 era of Musk's action model, intended to exert pressure on Congress. However, some also say that the consensus at Mar-a-Lago is that Musk has proven to be an effective Weapon to pressure Congress and a scapegoat for any backlash.
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
Direxion Daily Healthcare Bull 3X Shares To Go Ex-Dividend On December 23rd, 2024 With 0.116 USD Dividend Per Share
December 20th (Eastern Time) - $Direxion Daily Healthcare Bull 3X Shares(CURE.US)$ is trading ex-dividend on December 23rd, 2024.Shareholders of record on December 23rd, 2024 will receive 0.116 USD
Pfizer Gets FDA Accelerated Approval for Braftovi
Government Shutdown Threat: Stocks Wobble, Holiday Travel And Paychecks Could Face Delays: What You Need To Know
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
J.P. Morgan's Top Healthcare Stocks for 2025
Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher
Merck Downgraded by BMO Over Keytruda Concerns
RxSight Cut to Hold at Stifel on Competition Concerns
US Stock Preview | USA PCE data overall underperformed expectations, and the declines in the three major futures indices significantly narrowed; US stocks face another test: the largest "Triple Witching" day in history arrives tonight!
The latest weight loss drug's phase 3 trial results were below expectations, resulting in Novo-Nordisk A/S's shares dropping nearly 20% in Pre-Market Trading; the Trump Media Technology Group's shares fell over 4% in Pre-Market Trading as Trump transferred all his shares to a revocable REITs.
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Merck Disclosed Closing Of Exclusive Global License Agreement For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody From LaNova Medicine; Company To Record Pre-tax Charge Relating To Upfront Payment Of $588M, Or $0.18 Per Share, In Q4 2024...